New hope for tough cancers: trial tests personalized immune drug
NCT ID NCT07300891
Summary
This study is testing a personalized immunotherapy drug called tislelizumab for patients with advanced solid cancers that have stopped responding to standard treatments. It will enroll about 72 patients whose tumors show a specific genetic signature suggesting they might respond to this type of drug. The main goal is to see if the drug can shrink tumors in these carefully selected patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID CANCER PATIENTS UNEXPOSED TO IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.